Mechanisms of Diastolic Dysfunction in Cardiovascular Disease Myocardial reverse remodeling : how far can we rewind ?
暂无分享,去创建一个
[1] W. Paulus,et al. Myocardial Microvascular Inflammatory Endothelial Activation in Heart Failure With Preserved Ejection Fraction. , 2016, JACC. Heart failure.
[2] J. Wang,et al. Aerobic Interval Training Elicits Different Hemodynamic Adaptations Between Heart Failure Patients with Preserved and Reduced Ejection Fraction , 2016, American journal of physical medicine & rehabilitation.
[3] S. Sedej,et al. Myocardial hypertrophy and its role in heart failure with preserved ejection fraction. , 2015, Journal of applied physiology.
[4] R. D. de Boer,et al. Effects of sildenafil on invasive haemodynamics and exercise capacity in heart failure patients with preserved ejection fraction and pulmonary hypertension: a randomized controlled trial. , 2015, European heart journal.
[5] H. Maechler,et al. A porcine model of hypertensive cardiomyopathy: implications for heart failure with preserved ejection fraction. , 2015, American journal of physiology. Heart and circulatory physiology.
[6] C. D. dos Remedios,et al. Synergistic role of ADP and Ca2+ in diastolic myocardial stiffness , 2015, The Journal of physiology.
[7] C. Gavina. Determinants of left ventricular hypertrophy before and after surgical treatment of aortic stenosis: clinical, morphofunctional, genetic and molecular correlations , 2015 .
[8] D. Kitzman,et al. Exercise intolerance in heart failure with preserved ejection fraction: more than a heart problem , 2015, Journal of geriatric cardiology : JGC.
[9] N. Bray. Cardiovascular disease: PDE9A inhibition mends broken hearts , 2015, Nature Reviews Drug Discovery.
[10] A. Alsheikh-Ali,et al. Clinical characteristics, management, and outcomes of acute heart failure patients: observations from the Gulf acute heart failure registry (Gulf CARE) , 2015, European journal of heart failure.
[11] T. Thum,et al. MicroRNA signatures differentiate preserved from reduced ejection fraction heart failure , 2015, European journal of heart failure.
[12] F. Messerli,et al. Beta-blockers in heart failure with preserved ejection fraction: a meta-analysis , 2015, Heart Failure Reviews.
[13] E. Braunwald. The war against heart failure: the Lancet lecture , 2015, The Lancet.
[14] G. Filippatos,et al. Drug therapy for patients with systolic heart failure after the PARADIGM-HF trial: in need of a new paradigm of LCZ696 implementation in clinical practice , 2015, BMC Medicine.
[15] Yongjun Li,et al. Effects of miRNA-455 on cardiac hypertrophy induced by pressure overload , 2015, International journal of molecular medicine.
[16] G. Biondi-Zoccai,et al. Heart failure with preserved ejection fraction: refocusing on diastole. , 2015, International journal of cardiology.
[17] R. Hui,et al. MiR-451 is decreased in hypertrophic cardiomyopathy and regulates autophagy by targeting TSC1 , 2014, Journal of cellular and molecular medicine.
[18] M. Zile,et al. Cardiac-restricted overexpression or deletion of tissue inhibitor of matrix metalloproteinase-4: differential effects on left ventricular structure and function following pressure overload-induced hypertrophy. , 2014, American Journal of Physiology. Heart and Circulatory Physiology.
[19] Akshay S. Desai,et al. Cardiac Structure and Function and Prognosis in Heart Failure With Preserved Ejection Fraction: Findings From the Echocardiographic Study of the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) Trial , 2014, Circulation. Heart failure.
[20] J. Baugh,et al. Role of inflammation in the pathogenesis of heart failure with preserved ejection fraction and its potential as a therapeutic target , 2014, Heart Failure Reviews.
[21] D. Kass,et al. Heart failure with preserved ejection fraction: mechanisms, clinical features, and therapies. , 2014, Circulation research.
[22] A. Maitra,et al. miR-181c Regulates the Mitochondrial Genome, Bioenergetics, and Propensity for Heart Failure In Vivo , 2014, PloS one.
[23] L. Tavazzi,et al. In-hospital and 1-year outcomes of acute heart failure patients according to presentation (de novo vs. worsening) and ejection fraction. Results from IN-HF Outcome Registry. , 2014, International journal of cardiology.
[24] B. Schroen,et al. microRNA-122 down-regulation may play a role in severe myocardial fibrosis in human aortic stenosis through TGF-β1 up-regulation. , 2014, Clinical science.
[25] Sanjiv J. Shah,et al. Developing therapies for heart failure with preserved ejection fraction: current state and future directions. , 2014, JACC. Heart failure.
[26] W. Linke,et al. S-Glutathionylation of Cryptic Cysteines Enhances Titin Elasticity by Blocking Protein Folding , 2014, Cell.
[27] P. Doevendans,et al. Inhibition of miR-25 Improves Cardiac Contractility in the Failing Heart , 2014, Nature.
[28] P. Barlis,et al. Therapeutic interventions for heart failure with preserved ejection fraction: A summary of current evidence. , 2014, World journal of cardiology.
[29] N. Nair,et al. Cardiac myosin-binding protein-C is a critical mediator of diastolic function , 2014, Pflügers Archiv - European Journal of Physiology.
[30] Fen Hu,et al. microRNA-21 promotes cardiac fibrosis and development of heart failure with preserved left ventricular ejection fraction by up-regulating Bcl-2. , 2014, International journal of clinical and experimental pathology.
[31] K. Shyu,et al. MicroRNA-208a Increases Myocardial Fibrosis via Endoglin in Volume Overloading Heart , 2014, PloS one.
[32] W. Paulus,et al. Myocardial Titin Hypophosphorylation Importantly Contributes to Heart Failure With Preserved Ejection Fraction in a Rat Metabolic Risk Model , 2013, Circulation. Heart failure.
[33] C. Abreu-Goodger,et al. microRNA-22 Promotes Heart Failure through Coordinate Suppression of PPAR/ERR-Nuclear Hormone Receptor Transcription , 2013, PloS one.
[34] Jiao Li,et al. MicroRNA-26 Was Decreased in Rat Cardiac Hypertrophy Model and May Be a Promising Therapeutic Target , 2013, Journal of cardiovascular pharmacology.
[35] W. Paulus,et al. Myocardial titin and collagen in cardiac diastolic dysfunction: partners in crime. , 2013, Circulation.
[36] D. Kass,et al. Mutation of the protein kinase I alpha leucine zipper domain produces hypertension and progressive left ventricular hypertrophy: a novel mouse model of age-dependent hypertensive heart disease. , 2013, The journals of gerontology. Series A, Biological sciences and medical sciences.
[37] Donald M Bers,et al. Calcium movements inside the sarcoplasmic reticulum of cardiac myocytes. , 2013, Journal of molecular and cellular cardiology.
[38] M. Zile,et al. Effects of Exercise on Left Ventricular Systolic and Diastolic Properties in Patients With Heart Failure and a Preserved Ejection Fraction Versus Heart Failure and a Reduced Ejection Fraction , 2013, Circulation. Heart failure.
[39] Dean Y. Li,et al. Magnitude and time course of changes induced by continuous-flow left ventricular assist device unloading in chronic heart failure: insights into cardiac recovery. , 2013, Journal of the American College of Cardiology.
[40] J. Metzger,et al. Calcium mishandling in diastolic dysfunction: mechanisms and potential therapies. , 2013, Biochimica et biophysica acta.
[41] W. Linke,et al. Deranged myofilament phosphorylation and function in experimental heart failure with preserved ejection fraction. , 2013, Cardiovascular research.
[42] R. Wachter,et al. Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial. , 2013, JAMA.
[43] L. Køber,et al. Decreased mitochondrial oxidative phosphorylation capacity in the human heart with left ventricular systolic dysfunction , 2013, European journal of heart failure.
[44] W. Linke,et al. Crucial Role for Ca2+/Calmodulin-Dependent Protein Kinase-II in Regulating Diastolic Stress of Normal and Failing Hearts via Titin Phosphorylation , 2013, Circulation research.
[45] M. Hori,et al. Effects of carvedilol on heart failure with preserved ejection fraction: the Japanese Diastolic Heart Failure Study (J‐DHF) , 2013, European journal of heart failure.
[46] Jun Ren,et al. Nitric oxide synthase uncoupling: a therapeutic target in cardiovascular diseases. , 2012, Vascular pharmacology.
[47] S. Solomon,et al. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial , 2012, The Lancet.
[48] Angela M. Lane,et al. Protein Kinase G Iα Inhibits Pressure Overload–Induced Cardiac Remodeling and Is Required for the Cardioprotective Effect of Sildenafil In Vivo , 2012, Journal of the American Heart Association.
[49] A. Leite-Moreira,et al. Left ventricular hypertrophy in isolated aortic stenosis: primetime for the ventricle. , 2012, Current pharmaceutical biotechnology.
[50] J. Bronzwaer,et al. Low Myocardial Protein Kinase G Activity in Heart Failure With Preserved Ejection Fraction , 2012, Circulation.
[51] A. Shoukas,et al. Alagebrium in combination with exercise ameliorates age-associated ventricular and vascular stiffness , 2012, Experimental Gerontology.
[52] T. Wynn,et al. Mechanisms of fibrosis: therapeutic translation for fibrotic disease , 2012, Nature Medicine.
[53] Anton J. Enright,et al. Targeted Deletion of MicroRNA-22 Promotes Stress-Induced Cardiac Dilation and Contractile Dysfunction , 2012, Circulation.
[54] N. Freemantle,et al. Relationship between plasma concentrations of N‐terminal pro brain natriuretic peptide and the characteristics and outcome of patients with a clinical diagnosis of diastolic heart failure: a report from the PEP‐CHF study , 2012, European journal of heart failure.
[55] I. Sjaastad,et al. A mouse model of reverse cardiac remodelling following banding‐debanding of the ascending aorta , 2012, Acta physiologica.
[56] Salil Sharma,et al. Repression of miR-142 by p300 and MAPK is required for survival signalling via gp130 during adaptive hypertrophy , 2012, EMBO molecular medicine.
[57] A. Coulton,et al. Cardiac myosin binding protein C and its phosphorylation regulate multiple steps in the cross-bridge cycle of muscle contraction. , 2012, Biochemistry.
[58] B. Borlaug,et al. Letter by Forfia and Borlaug regarding article, "Pulmonary hypertension in heart failure with preserved ejection fraction: a target of phosphodiesterase-5 inhibition in a 1-year study". , 2012, Circulation.
[59] P. Vardas,et al. Effects of the long‐term administration of nebivolol on the clinical symptoms, exercise capacity, and left ventricular function of patients with diastolic dysfunction: results of the ELANDD study , 2012, European journal of heart failure.
[60] D. Kass,et al. Pressure-Overload–Induced Subcellular Relocalization/Oxidation of Soluble Guanylyl Cyclase in the Heart Modulates Enzyme Stimulation , 2012, Circulation research.
[61] K. Chowdhury,et al. The miRNA-212/132 family regulates both cardiac hypertrophy and cardiomyocyte autophagy , 2012, Nature Communications.
[62] M. Zubaid,et al. Peripheral Arterial Disease in Patients Presenting with Acute Coronary Syndrome in Six Middle Eastern Countries , 2011, International journal of vascular medicine.
[63] R. McKelvie,et al. Prevalence and Significance of Alterations in Cardiac Structure and Function in Patients With Heart Failure and a Preserved Ejection Fraction , 2011, Circulation.
[64] B. Long,et al. Cardiac Hypertrophy Is Positively Regulated by MicroRNA miR-23a* , 2011, The Journal of Biological Chemistry.
[65] S. Fröhling,et al. Exercise training improves exercise capacity and diastolic function in patients with heart failure with preserved ejection fraction: results of the Ex-DHF (Exercise training in Diastolic Heart Failure) pilot study. , 2011, Journal of the American College of Cardiology.
[66] V. Ganjam,et al. Low-intensity interval exercise training attenuates coronary vascular dysfunction and preserves Ca²⁺-sensitive K⁺ current in miniature swine with LV hypertrophy. , 2011, American journal of physiology. Heart and circulatory physiology.
[67] D. Phelan,et al. Can emerging biomarkers of myocardial remodelling identify asymptomatic hypertensive patients at risk for diastolic dysfunction and diastolic heart failure? , 2011, European journal of heart failure.
[68] T. Carrel,et al. S100A1 genetically targeted therapy reverses dysfunction of human failing cardiomyocytes. , 2011, Journal of the American College of Cardiology.
[69] P. Most,et al. S100A1 gene therapy for heart failure: a novel strategy on the verge of clinical trials. , 2011, Journal of molecular and cellular cardiology.
[70] J. Magovern,et al. LV reverse remodeling imparted by aortic valve replacement for severe aortic stenosis; is it durable? A cardiovascular MRI study sponsored by the American Heart Association , 2011, Journal of cardiothoracic surgery.
[71] J. McMullen,et al. The athlete's heart vs. the failing heart: can signaling explain the two distinct outcomes? , 2011, Physiology.
[72] P. Steendijk,et al. Cardiac Inflammation Contributes to Changes in the Extracellular Matrix in Patients With Heart Failure and Normal Ejection Fraction , 2011, Circulation. Heart failure.
[73] G. Condorelli,et al. MicroRNA-199b targets the nuclear kinase Dyrk1a in an auto-amplification loop promoting calcineurin/NFAT signalling , 2010, Nature Cell Biology.
[74] M. Simoons,et al. Recovery of Long‐Axis Left Ventricular Function after Aortic Valve Replacement in Patients with Severe Aortic Stenosis , 2010, Echocardiography.
[75] P. Fesler,et al. Dietary Sodium, Aldosterone, and Left Ventricular Mass Changes During Long-Term Inhibition of the Renin-Angiotensin System , 2010, Hypertension.
[76] C. Baines,et al. Low-intensity aerobic interval training attenuates pathological left ventricular remodeling and mitochondrial dysfunction in aortic-banded miniature swine. , 2010, American journal of physiology. Heart and circulatory physiology.
[77] Qing Jing,et al. MicroRNAs are dynamically regulated in hypertrophic hearts, and miR‐199a is essential for the maintenance of cell size in cardiomyocytes , 2010, Journal of cellular physiology.
[78] Amir Lerman,et al. Global cardiovascular reserve dysfunction in heart failure with preserved ejection fraction. , 2010, Journal of the American College of Cardiology.
[79] J. Corbin,et al. cGMP-Dependent Protein Kinases and cGMP Phosphodiesterases in Nitric Oxide and cGMP Action , 2010, Pharmacological Reviews.
[80] J. Hare,et al. Impaired S-Nitrosylation of the Ryanodine Receptor Caused by Xanthine Oxidase Activity Contributes to Calcium Leak in Heart Failure* , 2010, The Journal of Biological Chemistry.
[81] F. Mohr,et al. Decreased rates of substrate oxidation ex vivo predict the onset of heart failure and contractile dysfunction in rats with pressure overload. , 2010, Cardiovascular research.
[82] R. McKelvie,et al. Mode of Death in Patients With Heart Failure and a Preserved Ejection Fraction: Results From the Irbesartan in Heart Failure With Preserved Ejection Fraction Study (I-Preserve) Trial , 2010, Circulation.
[83] B. Long,et al. miR-9 and NFATc3 Regulate Myocardin in Cardiac Hypertrophy* , 2010, The Journal of Biological Chemistry.
[84] S. Dikalov,et al. Uncoupled Cardiac Nitric Oxide Synthase Mediates Diastolic Dysfunction , 2010, Circulation.
[85] M. Gautel,et al. Distinct Sarcomeric Substrates Are Responsible for Protein Kinase D-mediated Regulation of Cardiac Myofilament Ca2+ Sensitivity and Cross-bridge Cycling* , 2009, The Journal of Biological Chemistry.
[86] Siegfried Labeit,et al. PKC Phosphorylation of Titin’s PEVK Element: A Novel and Conserved Pathway for Modulating Myocardial Stiffness , 2009, Circulation research.
[87] W. Linke,et al. Modulation of titin-based stiffness by disulfide bonding in the cardiac titin N2-B unique sequence. , 2009, Biophysical journal.
[88] A. Cohen-Solal,et al. Beta-blockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection fraction: Data From SENIORS (Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors With Heart Failure). , 2009, Journal of the American College of Cardiology.
[89] M. MacCoss,et al. Overexpression of Catalase Targeted to Mitochondria Attenuates Murine Cardiac Aging , 2009, Circulation.
[90] J. Bronzwaer,et al. Hypophosphorylation of the Stiff N2B Titin Isoform Raises Cardiomyocyte Resting Tension in Failing Human Myocardium , 2009, Circulation research.
[91] W. Paulus,et al. Molecular determinants of heart failure with normal left ventricular ejection fraction , 2009, Pharmacological reports : PR.
[92] W. Rottbauer,et al. MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts , 2008, Nature.
[93] P. Powers,et al. Acceleration of Crossbridge Kinetics by Protein Kinase A Phosphorylation of Cardiac Myosin Binding Protein C Modulates Cardiac Function , 2008, Circulation research.
[94] Jeffrey E. Thatcher,et al. Dysregulation of microRNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosis , 2008, Proceedings of the National Academy of Sciences.
[95] G. Tenderich,et al. Ranolazine improves diastolic dysfunction in isolated myocardium from failing human hearts--role of late sodium current and intracellular ion accumulation. , 2008, Journal of molecular and cellular cardiology.
[96] W. Little,et al. Observational studies of statins in heart failure with preserved systolic function. , 2008, Heart failure clinics.
[97] Z. Massy,et al. Prognostic impact of angiotensin-converting enzyme inhibitor therapy in diastolic heart failure. , 2008, The American journal of cardiology.
[98] J. Foody,et al. Effect of statins, angiotensin-converting enzyme inhibitors, and beta blockers on survival in patients >or=65 years of age with heart failure and preserved left ventricular systolic function. , 2008, The American journal of cardiology.
[99] R. Moss,et al. Differential Roles of Cardiac Myosin-Binding Protein C and Cardiac Troponin I in the Myofibrillar Force Responses to Protein Kinase A Phosphorylation , 2007, Circulation research.
[100] Nancy M Albert,et al. Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE-HF Registry. , 2007, Journal of the American College of Cardiology.
[101] D. J. Veldhuisen,et al. Prescription of beta‐blockers in patients with advanced heart failure and preserved left ventricular ejection fraction. Clinical implications and survival , 2007, European journal of heart failure.
[102] D. Kass,et al. Impaired Chronotropic and Vasodilator Reserves Limit Exercise Capacity in Patients With Heart Failure and a Preserved Ejection Fraction , 2006, Circulation.
[103] J. Fleg,et al. Heart failure with preserved ejection fraction. , 2006, The New England journal of medicine.
[104] Y. Mori,et al. Impact of the Angiotensin II Receptor Antagonist, Losartan, on Myocardial Fibrosis in Patients with End-Stage Renal Disease: Assessment by Ultrasonic Integrated Backscatter and Biochemical Markers , 2005, Hypertension Research.
[105] P. Carmeliet,et al. Increased Cardiac Expression of Tissue Inhibitor of Metalloproteinase-1 and Tissue Inhibitor of Metalloproteinase-2 Is Related to Cardiac Fibrosis and Dysfunction in the Chronic Pressure-Overloaded Human Heart , 2005, Circulation.
[106] D. Sane,et al. Statin Therapy May Be Associated With Lower Mortality in Patients With Diastolic Heart Failure: A Preliminary Report , 2005, Circulation.
[107] M. Emond,et al. Extension of Murine Life Span by Overexpression of Catalase Targeted to Mitochondria , 2005, Science.
[108] D. Kass,et al. Oxidant stress from nitric oxide synthase-3 uncoupling stimulates cardiac pathologic remodeling from chronic pressure load. , 2005, The Journal of clinical investigation.
[109] J. Guerrero,et al. In vivo gene transfer of parvalbumin improves diastolic function in aged rat hearts. , 2005, Cardiovascular research.
[110] Frank J Giordano,et al. Oxygen, oxidative stress, hypoxia, and heart failure. , 2005, The Journal of clinical investigation.
[111] Istvan Edes,et al. Cardiomyocyte Stiffness in Diastolic Heart Failure , 2005, Circulation.
[112] A. Cohen-Solal,et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). , 2005, European heart journal.
[113] D. Kass,et al. Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy , 2005, Nature Medicine.
[114] V. Regitz-Zagrosek,et al. Regulation of matrix metalloproteinases and their inhibitors in the left ventricular myocardium of patients with aortic stenosis , 2004, Journal of Molecular Medicine.
[115] J. Cohn,et al. Severity of left ventricular remodeling defines outcomes and response to therapy in heart failure: Valsartan heart failure trial (Val-HeFT) echocardiographic data. , 2004, Journal of the American College of Cardiology.
[116] B. Andersson,et al. Effect of carvedilol on diastolic function in patients with diastolic heart failure and preserved systolic function. Results of the Swedish Doppler‐echocardiographic study (SWEDIC) , 2004, European journal of heart failure.
[117] L. Badano,et al. Prevalence, clinical characteristics, quality of life, and prognosis of patients with congestive heart failure and isolated left ventricular diastolic dysfunction. , 2004, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.
[118] G. J. van der Vusse,et al. Metabolic remodelling of the failing heart: the cardiac burn-out syndrome? , 2004, Cardiovascular research.
[119] S. Rubin,et al. Inflammatory Markers and Onset of Cardiovascular Events: Results From the Health ABC Study , 2003, Circulation.
[120] Karl Swedberg,et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial , 2003, The Lancet.
[121] J. Metzger,et al. Myofilament Calcium Sensitivity and Cardiac Disease: Insights From Troponin I Isoforms and Mutants , 2002, Circulation research.
[122] Yiming Wu,et al. Changes in Titin Isoform Expression in Pacing-Induced Cardiac Failure Give Rise to Increased Passive Muscle Stiffness , 2002, Circulation.
[123] H. Drexler,et al. Inhibition of calcineurin-NFAT hypertrophy signaling by cGMP-dependent protein kinase type I in cardiac myocytes , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[124] D. Brutsaert,et al. New concepts in diastolic dysfunction and diastolic heart failure: Part II: causal mechanisms and treatment. , 2002, Circulation.
[125] Chu-Pak Lau,et al. Tissue Doppler Echocardiographic Evidence of Reverse Remodeling and Improved Synchronicity by Simultaneously Delaying Regional Contraction After Biventricular Pacing Therapy in Heart Failure , 2002, Circulation.
[126] C. Trautwein,et al. Gene Transfer of cGMP-Dependent Protein Kinase I Enhances the Antihypertrophic Effects of Nitric Oxide in Cardiomyocytes , 2002, Hypertension.
[127] John P. Gaughan,et al. Electrophysiological Alterations After Mechanical Circulatory Support in Patients With Advanced Cardiac Failure , 2001, Circulation.
[128] D. Burkhoff,et al. Comparison of Right and Left Ventricular Responses to Left Ventricular Assist Device Support in Patients With Severe Heart Failure: A Primary Role of Mechanical Unloading Underlying Reverse Remodeling , 2001, Circulation.
[129] E Fleck,et al. Activation of the cardiac renin-angiotensin system and increased myocardial collagen expression in human aortic valve disease. , 2001, Journal of the American College of Cardiology.
[130] C. Dellorusso,et al. In vivo acceleration of heart relaxation performance by parvalbumin gene delivery. , 2001, The Journal of clinical investigation.
[131] D. Burkhoff,et al. Chronic Unloading by Left Ventricular Assist Device Reverses Contractile Dysfunction and Alters Gene Expression in End-Stage Heart Failure , 2000, Circulation.
[132] F. Spinale,et al. A Matrix Metalloproteinase Induction/Activation System Exists in the Human Left Ventricular Myocardium and Is Upregulated in Heart Failure , 2000, Circulation.
[133] K. Weber,et al. Targeting pathological remodeling: concepts of cardioprotection and reparation. , 2000, Circulation.
[134] A. Gerdes,et al. Reverse remodeling of cardiac myocyte hypertrophy in hypertension and failure by targeting of the renin-angiotensin system. , 2000, Circulation.
[135] J. Cohn,et al. Cardiac remodeling--concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. Behalf of an International Forum on Cardiac Remodeling. , 2000, Journal of the American College of Cardiology.
[136] N. Freemantle,et al. Perindopril for elderly people with chronic heart failure: the PEP‐CHF study , 1999, European heart journal.
[137] S. Houser,et al. Myocyte recovery after mechanical circulatory support in humans with end-stage heart failure. , 1998, Circulation.
[138] A. Coats,et al. Mechanical support in dilated cardiomyopathy: signs of early left ventricular recovery. , 1997, The Annals of thoracic surgery.
[139] B. Lorell,et al. Failure to maintain a low ADP concentration impairs diastolic function in hypertrophied rat hearts. , 1997, Circulation.
[140] L. Katwa,et al. Angiotensin II stimulated expression of transforming growth factor-beta1 in cardiac fibroblasts and myofibroblasts. , 1997, Journal of molecular and cellular cardiology.
[141] D. Levy,et al. Left ventricular dilatation and the risk of congestive heart failure in people without myocardial infarction. , 1997, The New England journal of medicine.
[142] J. Cleutjens,et al. The role of matrix metalloproteinases in heart disease. , 1996, Cardiovascular research.
[143] I. Grupp,et al. Mitochondrial dysfunction accompanies diastolic dysfunction in diabetic rat heart. , 1996, The American journal of physiology.
[144] P. Timmermans,et al. The preclinical basis of the therapeutic evaluation of losartan , 1995, Journal of hypertension. Supplement : official journal of the International Society of Hypertension.
[145] M. Gautel,et al. Phosphorylation switches specific for the cardiac isoform of myosin binding protein‐C: a modulator of cardiac contraction? , 1995, The EMBO journal.
[146] O. Hess,et al. Normalization of diastolic dysfunction in aortic stenosis late after valve replacement. , 1995, Circulation.
[147] R. Kloner,et al. Reperfusion injury induces apoptosis in rabbit cardiomyocytes. , 1994, The Journal of clinical investigation.
[148] G. Cocco,et al. Effects of a New Metabolic Modulator, Ranolazine, on Exercise Tolerance in Angina Pectoris Patients Treated with β‐Blocker or Diltiazem , 1992, Journal of cardiovascular pharmacology.
[149] P. Armstrong,et al. Remodeling and reparation of the cardiovascular system. , 1992, Journal of the American College of Cardiology.
[150] O. Hess,et al. Regression of Coronary Artery Dimensions After Successful Aortic Valve Replacement , 1992, Circulation.
[151] L. J. Bean,et al. Phosphorylation of chicken cardiac C-protein by calcium/calmodulin-dependent protein kinase II. , 1991, The Journal of biological chemistry.
[152] H. Schunkert,et al. Increased rat cardiac angiotensin converting enzyme activity and mRNA expression in pressure overload left ventricular hypertrophy. Effects on coronary resistance, contractility, and relaxation. , 1990, The Journal of clinical investigation.
[153] D. Allen,et al. Myocardial contractile function during ischemia and hypoxia. , 1987, Circulation research.
[154] M. Mayr,et al. Myocardial metabolism of free fatty acids. Studies with 14C-labeled substrates in humans. , 1987, The Journal of clinical investigation.
[155] G. Naccarelli,et al. Congestive heart failure with normal systolic function. , 1984, The American journal of cardiology.
[156] W. Gaasch,et al. Left ventricular radius to wall thickness ratio. , 1979, The American journal of cardiology.
[157] A. Leite-Moreira,et al. Load independent impairment of reverse remodeling after valve replacement in hypertensive aortic stenosis patients. , 2014, International Journal of Cardiology.
[158] A. Leite-Moreira,et al. S100A1: a major player in cardiovascular performance. , 2014, Physiological research.
[159] A. Alsheikh-Ali,et al. Rationale, Design, Methodology and Hospital Characteristics of the First Gulf Acute Heart Failure Registry (Gulf CARE) , 2014, Heart views : the official journal of the Gulf Heart Association.
[160] R. Duisters,et al. MIRNA-133 AND MIRNA-30 REGULATE CONNECTIVE TISSUE GROWTH FACTOR: IMPLICATIONS FOR A ROLE OF MIRNAS IN MYOCARDIAL MATRIX REMODELING , 2013 .
[161] M. MacCoss,et al. Mitochondrial proteome remodelling in pressure overload-induced heart failure: the role of mitochondrial oxidative stress. , 2012, Cardiovascular research.
[162] F. Jamous,et al. Pulmonary Hypertension in Heart Failure With Preserved Ejection Fraction: A Target of Phosphodiesterase-5 Inhibition in a 1-Year Study , 2012 .
[163] E. Takimoto. Cyclic GMP-dependent signaling in cardiac myocytes. , 2012, Circulation journal : official journal of the Japanese Circulation Society.
[164] A. Castro‐Beiras,et al. Differences in Outcome of Heart Failure With Preserved or Depressed Systolic Function in Patients Older Than 70 Years Who Receive Beta Blockers , 2012 .
[165] G. MacGowan,et al. Letter by Gordon et al regarding article, "Pulmonary hypertension in heart failure with preserved ejection fraction: a target of phosphodiesterase-5 inhibition in a 1-year study". , 2012, Circulation.
[166] I. Sjaastad,et al. Collagen isoform shift during the early phase of reverse left ventricular remodelling after relief of pressure overload. , 2011, European heart journal.
[167] J. Bronzwaer,et al. Diastolic Stiffness of the Failing Diabetic Heart: Importance of Fibrosis, Advanced Glycation End Products, and Myocyte Resting Tension , 2008, Circulation.
[168] N. Frangogiannis,et al. The role of TGF-beta signaling in myocardial infarction and cardiac remodeling. , 2007, Cardiovascular research.
[169] P. Buttrick,et al. PKCepsilon increases phosphorylation of the cardiac myosin binding protein C at serine 302 both in vitro and in vivo. , 2007, Biochemistry.